← All trials
NCT02003222
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 23, 2013
- Primary completion
- Jun 30, 2018
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 360
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- ECOG-ACRIN Cancer Research GroupOverall official - principal investigator
Drugs studied
- mercaptopurine
- mercaptopurine
- urea
- urea
- blinatumomab
- prednisone
- prednisone
- naltrexone
- naltrexone
- vincristine
- vincristine
- pegaspargase
- pegaspargase
- allogeneic hematopoietic stem cells
- allogeneic hematopoietic stem cells
- cyclophosphamide
- cyclophosphamide
- daunorubicin
- daunorubicin
- rituximab
- rituximab
- etoposide
- etoposide
- cytarabine
- cytarabine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.